High-Sensitivity Troponin I in Atrial Fibrillation: Impact of rate and rhythm control and associations with biomarkers related to atrial fibrillation pathophysiology
Metadata
Show metadataAppears in the following Collection
- Institutt for klinisk medisin [10728]
Abstract
Cardiac troponins are intracellular proteins existing solely in cardiac myocytes. Highly sensitive troponin assays have revealed low levels of circulating troponins in individuals with atrial fibrillation that have been associated with increased risk of stroke and death. However, it is not clear whether the levels of troponins observed in atrial fibrillation are independent of underlying cardiovascular disease. The potential impact of different treatment modalities on troponin levels in atrial fibrillation is largely unknown. In this project we have used a highly sensitive assay for quantifying levels of Troponin I in three atrial fibrillation research projects conducted at Bærum Hospital. One of our findings was that atrial fibrillation was not independently associated with levels of Troponin I. We showed that Troponin I levels were unchanged six months after restoration of sinus rhythm by electrical cardioversion. Intriguingly, we found that Troponin I levels were lowered by rate-reducing drugs. This thesis has provided new information on the role of Troponin I in atrial fibrillation, which has clinical relevance as well as implications for future research.List of papers
Paper I: Horjen AW, Ulimoen SR, Enger S, Berge T, Ihle-Hansen H, Norseth J, Tveit A. Impact of atrial fibrillation on levels of high-sensitivity troponin I in a 75-year-old population. DOI:10.3109/00365513.2015.1011224. Scandinavian Journal of Clinical & Laboratory Investigation 2015; 75(4): 308-313. The paper is not available in DUO due to publisher restrictions. The published version is available at https://doi.org/10.3109/00365513.2015.1011224 |
Paper II: Horjen AW, Ulimoen SR, Enger S, Norseth J, Seljeflot I, Arnesen H, Tveit A. Troponin I levels in permanent atrial fibrillation-impact of rate control and exercise testing. DOI: 10.1186/s12872-016-0255-x. BMC Cardiovascular Disorders 2016;16(1): 79. The article is included in the thesis. Also available at http://urn.nb.no/URN:NBN:no-62133 |
Paper III: Horjen AW, Ulimoen SR, Seljeflot I, Smith P, Arnesen H, Norseth J, Tveit A. High-sensitivity troponin I and rhythm outcome after electrical cardioversion for persistent atrial fibrillation. Cardiology 2015;133(4): 233-238. DOI: 10.1159/000442249. The paper is not available in DUO due to publisher restrictions. The published version is available at https://doi.org/10.1159/000442249 |
Paper IV: Horjen AW, Ulimoen SR, Norseth J, Svendsen JH, Smith P, Arnesen H, Seljeflot I, Tveit A. High-sensitivity troponin I in persistent atrial fibrillation – relation to NT-proBNP and markers of inflammation and ha1500112377 emostasis. Submitted January 2018. To be published. The paper is not available in DUO awaiting publishing. |